Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome

Aurich, Stefanie; Simon, Jan C.; Treudler, Regina

doi:10.1111/jdv.14202

Cited by 12 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 1 shows that some studies showed significant improvement in symptoms in male and female patients with NUV alone [2–6] and in combination with systemic lupus erythematosus [7] and Churg–Strauss syndrome [8]. However, studies in patients with HUV show conflicting results: one with major organ involvement showed only minimal improvement [9], whereas a patient without major organ involvement showed complete resolution. None of these studies reported adverse events in relation to omalizumab.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab

Brito

Huebner

Murrell

et al. 2018

Clin Transl Allergy

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…However, studies in patients with HUV show conflicting results: one with major organ involvement showed only minimal improvement [9], whereas a patient without major organ involvement showed complete resolution. None of these studies reported adverse events in relation to omalizumab.…”

mentioning

confidence: 99%

Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab

Brito

Huebner

Murrell

et al. 2018

Clin Transl Allergy

View full text Add to dashboard Cite

show abstract

“…HUV syndrome (HUVS) is a rare immune complex medi-ated disease which has distinct pathophysiology and outcomes. Aurich et al 15 reported that omalizumab is not effective in HUVS. This suggests the pathophysiology of HUVS is significantly different from chronic spontaneous urticaria (CSU) and NUV.…”

Section: Discussionmentioning

confidence: 99%

Omalizumab as a Succesfull Therapy in Normocomplementemic Urticarial Vasculitis: A Series of Four Patients and Review of the Literature

et al. 2019

View full text Add to dashboard Cite

Urticarial vasculitis is an eruption characterized by inflamed itchy or painful red papules or plaques that resemble urticaria but last longer than 24 hours and heal with residual pigmentation or purpura. Histopathologically, urticarial vasculitis presents as leukocytoclastic vasculitis with perivascular infiltrate and fibrin deposits. The treatment options are oral antihistamines, oral corticosteroids, dapsone, colchicine and hydroxychloroquine. We report four cases with normocomplementemic urticarial vasculitis who were treated with omalizumab and a brief review of the literature on the use of omalizumab in normocomplementemic urticarial vasculitis.

show abstract

“…Table 1 shows that some studies showed significant improvement in symptoms in male and female patients with NUV alone [2][3][4][5][6] and in combination with systemic lupus erythematosus [7] and Churg-Strauss syndrome [8]. However, studies in patients with HUV show conflicting results: one with major organ involvement showed only minimal improvement [9], whereas a patient without major organ involvement showed complete resolution. None of these studies reported adverse events in relation to omalizumab.…”

Section: Marianne De Brito and Gisela Huebner Have Contributed Equallmentioning

confidence: 99%